Pilot Study of the Utility of Empiric Antibiotic Therapy for Suspected ICU-Acquired Infection

NCT00438269 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Nosocomial Infection
Pneumonia
Systemic Inflammatory Response Syndrome
Critical Illness
Pyrexia

Interventions

DRUG: Site-specific empiric regimens included: Meropenem
DRUG: Piperacillin/tazobactam
DRUG: Ciprofloxacin and cefazolin +/- metronidazole

Sponsor

Canadian Critical Care Trials Group

Collaborators

[object Object]